Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis

NCT01332019 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT01332019
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01332019 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis
Lead sponsor
Biogen
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2011
Completion date
October 31, 2015
Enrollment
1,077 (actual)
Sites
151

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing multiple sclerosis